Nanoco’s FY26 trading update confirms continued progress with its first Asian chemical customer, with all first-year milestones under the three-year joint development agreement (JDA) on track and volumes expected to more than double in FY27, albeit from a small base. Discussions with the second Asian customer remain ongoing, following a small programme extension in June.
FY26 revenue of £11.3m includes £9.8m of licence income, principally relating to the historic Samsung litigation settlement, for which cash was received in previous years. Underlying revenue of £1.5m was in line with expectations. Adjusted EBITDA of £6.1m and year-end cash of £9.3m were slightly ahead of expectations. Restructuring has reduced the gross monthly cash cost base to £0.3–0.4m from £0.5m in FY25, extending the financial runway for commercial development.
The update supports our view that Nanoco has the financial flexibility to progress its commercial opportunities, primarily in sensing. The expected increase in JDA volumes in FY27 is encouraging, although the transition to commercial scale production remains the critical next step.
The shareholder consultation following the board’s decision in June to adjourn a proposed delisting after shareholder opposition remains ongoing. The board is reviewing submissions before determining its next steps.
Healthcare | Comment
Healthcare | Comment
Financials | Comment
Healthcare | Comment
Consumer | Comment